Business Combinations and Acquisitions - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions |
|
|
|
|
1 Months Ended |
2 Months Ended |
4 Months Ended |
12 Months Ended |
Dec. 01, 2021 |
Oct. 20, 2021 |
Dec. 18, 2020 |
Sep. 01, 2020 |
Feb. 28, 2021 |
Dec. 31, 2021 |
Oct. 19, 2021 |
Dec. 31, 2021 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2019 |
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
|
|
|
$ 1,662.6
|
$ 677.4
|
$ 1,662.6
|
$ 681.5
|
$ 522.6
|
$ 511.6
|
GAAP purchase consideration, net of cash acquired |
|
|
|
|
|
$ 58.6
|
$ 0.9
|
|
$ 290.1
|
$ 55.7
|
$ 9.1
|
Payments to acquire businesses gross |
|
$ 1,300.0
|
|
|
|
|
|
|
|
|
|
Customer relationships | Minimum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
6 years
|
10 years
|
|
|
|
|
6 years
|
6 years
|
6 years
|
|
Customer relationships | Maximum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
13 years
|
11 years
|
|
|
|
|
13 years
|
17 years
|
15 years
|
|
Developed technology | Minimum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
5 years
|
7 years
|
|
|
|
|
5 years
|
3 years
|
3 years
|
|
Developed technology | Maximum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
16 years
|
10 years
|
|
|
|
|
16 years
|
16 years
|
16 years
|
|
Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
10 years
|
7 years
|
|
|
|
|
|
|
|
|
Trade names | Minimum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
|
|
|
|
|
|
3 years
|
5 years
|
5 years
|
|
Trade names | Maximum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
|
|
|
|
|
|
10 years
|
9 years
|
9 years
|
|
Distributor relationships | Minimum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
7 years
|
|
|
|
|
|
7 years
|
|
|
|
Distributor relationships | Maximum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
13 years
|
|
|
|
|
|
13 years
|
|
|
|
Backlog and other | Minimum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
1 year
|
|
|
|
|
|
1 year
|
1 year
|
1 year
|
|
Backlog and other | Maximum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
4 years
|
|
|
|
|
|
4 years
|
9 years
|
9 years
|
|
Noncompete Agreements |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
1 year
|
|
|
|
|
|
|
|
|
|
Noncompete Agreements | Minimum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
|
2 years
|
|
|
|
|
|
|
|
|
Noncompete Agreements | Maximum |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
|
|
3 years
|
|
|
|
|
|
|
|
|
Mirion TopCo |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Date of acquisition |
|
Oct. 20, 2021
|
|
|
|
|
|
|
|
|
|
Segment |
|
Total
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
$ 1,639.0
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
821.0
|
|
|
|
|
|
|
|
|
|
Cash |
|
101.9
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
114.3
|
|
|
|
|
|
|
|
|
|
Cost in excess of billings |
|
63.6
|
|
|
|
|
|
|
|
|
|
Inventory |
|
144.6
|
|
|
|
|
|
|
|
|
|
Property, Plant and Equipment |
|
126.4
|
|
|
|
|
|
|
|
|
|
Other current and non-current assets |
|
24.3
|
|
|
|
|
|
|
|
|
|
Right of use assets |
|
43.3
|
|
|
|
|
|
|
|
|
|
Other non-current assets |
|
17.0
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
(148.3)
|
|
|
|
|
|
|
|
|
|
Current lease liability |
|
(8.8)
|
|
|
|
|
|
|
|
|
|
Deferred contract revenue |
|
(58.9)
|
|
|
|
|
|
|
|
|
|
Notes payable assumed |
|
(2.9)
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
(242.1)
|
|
|
|
|
|
|
|
|
|
Minority interest |
|
(2.1)
|
|
|
|
|
|
|
|
|
|
Net tangible assets acquired |
|
172.3
|
|
|
|
|
|
|
|
|
|
Purchase consideration |
|
2,632.3
|
|
|
|
|
|
|
|
|
|
Less: cash acquired |
|
(101.9)
|
|
|
|
|
|
|
|
|
|
GAAP purchase consideration, net of cash acquired |
|
2,530.4
|
|
|
|
|
|
|
|
|
|
Mirion TopCo | Customer relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
338.8
|
|
|
|
|
|
|
|
|
|
Mirion TopCo | Developed technology |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
234.6
|
|
|
|
|
|
|
|
|
|
Mirion TopCo | Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
100.5
|
|
|
|
|
|
|
|
|
|
Mirion TopCo | Distributor relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
61.1
|
|
|
|
|
|
|
|
|
|
Mirion TopCo | Backlog and other |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
81.5
|
|
|
|
|
|
|
|
|
|
Mirion TopCo | Noncompete Agreements |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
$ 4.5
|
|
|
|
|
|
|
|
|
|
Medical | Mirion TopCo |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Segment |
|
Medical
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
$ 675.2
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
330.5
|
|
|
|
|
|
|
|
|
|
Cash |
|
7.8
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
44.0
|
|
|
|
|
|
|
|
|
|
Cost in excess of billings |
|
0.0
|
|
|
|
|
|
|
|
|
|
Inventory |
|
25.1
|
|
|
|
|
|
|
|
|
|
Property, Plant and Equipment |
|
52.6
|
|
|
|
|
|
|
|
|
|
Other current and non-current assets |
|
5.8
|
|
|
|
|
|
|
|
|
|
Right of use assets |
|
22.3
|
|
|
|
|
|
|
|
|
|
Other non-current assets |
|
8.0
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
(31.9)
|
|
|
|
|
|
|
|
|
|
Current lease liability |
|
(4.1)
|
|
|
|
|
|
|
|
|
|
Deferred contract revenue |
|
(34.7)
|
|
|
|
|
|
|
|
|
|
Notes payable assumed |
|
(1.8)
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
(70.6)
|
|
|
|
|
|
|
|
|
|
Minority interest |
|
0.0
|
|
|
|
|
|
|
|
|
|
Net tangible assets acquired |
|
22.5
|
|
|
|
|
|
|
|
|
|
Medical | Mirion TopCo | Customer relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
152.7
|
|
|
|
|
|
|
|
|
|
Medical | Mirion TopCo | Developed technology |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
66.3
|
|
|
|
|
|
|
|
|
|
Medical | Mirion TopCo | Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
36.8
|
|
|
|
|
|
|
|
|
|
Medical | Mirion TopCo | Distributor relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
52.5
|
|
|
|
|
|
|
|
|
|
Medical | Mirion TopCo | Backlog and other |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
17.7
|
|
|
|
|
|
|
|
|
|
Medical | Mirion TopCo | Noncompete Agreements |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
$ 4.5
|
|
|
|
|
|
|
|
|
|
Medical | CIRS |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Date of acquisition |
Dec. 01, 2021
|
|
|
|
|
|
|
|
|
|
|
Segment |
Medical
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
$ 35.0
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
21.8
|
|
|
|
|
|
|
|
|
|
|
Cash |
1.0
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
1.6
|
|
|
|
|
|
|
|
|
|
|
Inventory |
2.0
|
|
|
|
|
|
|
|
|
|
|
Property, Plant and Equipment |
0.4
|
|
|
|
|
|
|
|
|
|
|
Operating ROU assets |
3.8
|
|
|
|
|
|
|
|
|
|
|
Current liabilities |
(0.5)
|
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
(10.0)
|
|
|
|
|
|
|
|
|
|
|
Net tangible assets acquired |
(1.7)
|
|
|
|
|
|
|
|
|
|
|
Purchase consideration |
55.1
|
|
|
|
|
|
|
|
|
|
|
Less: cash acquired |
(1.0)
|
|
|
|
|
|
|
|
|
|
|
GAAP purchase consideration, net of cash acquired |
54.1
|
|
|
|
|
|
|
|
|
|
|
Acquiree revenue post acquisition through the period ended |
1.5
|
|
|
|
|
|
|
|
|
|
|
Acquiree income (loss) from operations post acquisition through the period ended |
(0.1)
|
|
|
|
|
|
|
|
|
|
|
Medical | CIRS | Customer relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
$ 1.6
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
7 years
|
|
|
|
|
|
|
|
|
|
|
Medical | CIRS | Developed technology |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
$ 19.2
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
5 years
|
|
|
|
|
|
|
|
|
|
|
Medical | CIRS | Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
$ 0.4
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
3 years
|
|
|
|
|
|
|
|
|
|
|
Medical | CIRS | Backlog and other |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
$ 0.6
|
|
|
|
|
|
|
|
|
|
|
Original Average Life in Years |
2 years
|
|
|
|
|
|
|
|
|
|
|
Medical | Biodex |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Date of acquisition |
|
|
|
Sep. 01, 2020
|
|
|
|
|
|
|
|
Segment |
|
|
|
Medical
|
|
|
|
|
|
|
|
Goodwill |
|
|
|
$ 11.1
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
|
6.6
|
|
|
|
|
|
|
|
Cash |
|
|
|
4.1
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
4.0
|
|
|
|
|
|
|
|
Inventory |
|
|
|
6.4
|
|
|
|
|
|
|
|
Property, Plant and Equipment |
|
|
|
1.0
|
|
|
|
|
|
|
|
Other current and non-current assets |
|
|
|
0.6
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
(2.6)
|
|
|
|
|
|
|
|
Deferred contract revenue |
|
|
|
(0.2)
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
|
|
0.0
|
|
|
|
|
|
|
|
Net tangible assets acquired |
|
|
|
13.3
|
|
|
|
|
|
|
|
Purchase consideration |
|
|
|
31.0
|
|
|
|
|
|
|
|
Less: cash acquired |
|
|
|
(4.1)
|
|
|
|
|
|
|
|
GAAP purchase consideration, net of cash acquired |
|
|
|
26.9
|
|
|
|
|
|
|
|
Acquiree revenue post acquisition through the period ended |
|
|
|
32.6
|
|
|
|
|
|
|
|
Acquiree income (loss) from operations post acquisition through the period ended |
|
|
|
0.7
|
|
|
|
|
|
|
|
Medical | Biodex | Customer relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
|
2.3
|
|
|
|
|
|
|
|
Medical | Biodex | Developed technology |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
|
2.6
|
|
|
|
|
|
|
|
Medical | Biodex | Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
|
1.4
|
|
|
|
|
|
|
|
Medical | Biodex | Noncompete Agreements |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
|
$ 0.3
|
|
|
|
|
|
|
|
Medical | SNC |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Date of acquisition |
|
|
Dec. 18, 2020
|
|
|
|
|
|
|
|
|
Segment |
|
|
Medical
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
$ 130.2
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
125.5
|
|
|
|
|
|
|
|
|
Cash |
|
|
18.8
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
24.0
|
|
|
|
|
|
|
|
|
Inventory |
|
|
13.9
|
|
|
|
|
|
|
|
|
Property, Plant and Equipment |
|
|
5.9
|
|
|
|
|
|
|
|
|
Other current and non-current assets |
|
|
8.0
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
(9.3)
|
|
|
|
|
|
|
|
|
Deferred contract revenue |
|
|
(6.5)
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
|
(33.6)
|
|
|
|
|
|
|
|
|
Net tangible assets acquired |
|
|
21.2
|
|
|
|
|
|
|
|
|
Purchase consideration |
|
|
276.9
|
|
|
|
|
|
|
|
|
Less: cash acquired |
|
|
(18.8)
|
|
|
|
|
|
|
|
|
GAAP purchase consideration, net of cash acquired |
|
|
258.1
|
|
|
|
|
|
|
|
|
Acquiree revenue post acquisition through the period ended |
|
|
48.9
|
|
|
|
|
|
|
|
|
Acquiree income (loss) from operations post acquisition through the period ended |
|
|
(5.5)
|
|
|
|
|
|
|
|
|
Payments to acquire businesses gross |
|
|
|
|
$ 261.9
|
|
|
|
|
|
|
Business combination, deferred consideration |
|
|
|
|
$ 15.0
|
|
|
|
|
|
|
Medical | SNC | Customer relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
59.5
|
|
|
|
|
|
|
|
|
Medical | SNC | Developed technology |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
46.5
|
|
|
|
|
|
|
|
|
Medical | SNC | Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
12.0
|
|
|
|
|
|
|
|
|
Medical | SNC | Noncompete Agreements |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
|
$ 7.5
|
|
|
|
|
|
|
|
|
Industrial | Mirion TopCo |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Segment |
|
Industrial
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
$ 963.8
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
490.5
|
|
|
|
|
|
|
|
|
|
Cash |
|
39.5
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
70.3
|
|
|
|
|
|
|
|
|
|
Cost in excess of billings |
|
63.6
|
|
|
|
|
|
|
|
|
|
Inventory |
|
119.5
|
|
|
|
|
|
|
|
|
|
Property, Plant and Equipment |
|
72.7
|
|
|
|
|
|
|
|
|
|
Other current and non-current assets |
|
13.2
|
|
|
|
|
|
|
|
|
|
Right of use assets |
|
20.1
|
|
|
|
|
|
|
|
|
|
Other non-current assets |
|
9.0
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
(82.7)
|
|
|
|
|
|
|
|
|
|
Current lease liability |
|
(4.4)
|
|
|
|
|
|
|
|
|
|
Deferred contract revenue |
|
(24.2)
|
|
|
|
|
|
|
|
|
|
Notes payable assumed |
|
(1.1)
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
(147.7)
|
|
|
|
|
|
|
|
|
|
Minority interest |
|
(2.0)
|
|
|
|
|
|
|
|
|
|
Net tangible assets acquired |
|
145.8
|
|
|
|
|
|
|
|
|
|
Industrial | Mirion TopCo | Customer relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
186.1
|
|
|
|
|
|
|
|
|
|
Industrial | Mirion TopCo | Developed technology |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
168.3
|
|
|
|
|
|
|
|
|
|
Industrial | Mirion TopCo | Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
63.7
|
|
|
|
|
|
|
|
|
|
Industrial | Mirion TopCo | Distributor relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
8.6
|
|
|
|
|
|
|
|
|
|
Industrial | Mirion TopCo | Backlog and other |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
63.8
|
|
|
|
|
|
|
|
|
|
Industrial | Mirion TopCo | Noncompete Agreements |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
$ 0.0
|
|
|
|
|
|
|
|
|
|
Corporate and other | Mirion TopCo |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Segment |
|
Corporate
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
$ 0.0
|
|
|
|
|
|
|
|
|
|
Cash |
|
54.6
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
0.0
|
|
|
|
|
|
|
|
|
|
Cost in excess of billings |
|
0.0
|
|
|
|
|
|
|
|
|
|
Inventory |
|
0.0
|
|
|
|
|
|
|
|
|
|
Property, Plant and Equipment |
|
1.1
|
|
|
|
|
|
|
|
|
|
Other current and non-current assets |
|
5.3
|
|
|
|
|
|
|
|
|
|
Right of use assets |
|
0.9
|
|
|
|
|
|
|
|
|
|
Other non-current assets |
|
0.0
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
(33.7)
|
|
|
|
|
|
|
|
|
|
Current lease liability |
|
(0.3)
|
|
|
|
|
|
|
|
|
|
Deferred contract revenue |
|
0.0
|
|
|
|
|
|
|
|
|
|
Notes payable assumed |
|
0.0
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities |
|
(23.8)
|
|
|
|
|
|
|
|
|
|
Minority interest |
|
(0.1)
|
|
|
|
|
|
|
|
|
|
Net tangible assets acquired |
|
4.0
|
|
|
|
|
|
|
|
|
|
Corporate and other | Mirion TopCo | Customer relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
0.0
|
|
|
|
|
|
|
|
|
|
Corporate and other | Mirion TopCo | Developed technology |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
0.0
|
|
|
|
|
|
|
|
|
|
Corporate and other | Mirion TopCo | Trade names |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
0.0
|
|
|
|
|
|
|
|
|
|
Corporate and other | Mirion TopCo | Distributor relationships |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
0.0
|
|
|
|
|
|
|
|
|
|
Corporate and other | Mirion TopCo | Backlog and other |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
0.0
|
|
|
|
|
|
|
|
|
|
Corporate and other | Mirion TopCo | Noncompete Agreements |
|
|
|
|
|
|
|
|
|
|
|
Business Combination, Separately Recognized Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amortizable intangible assets |
|
$ 0.0
|
|
|
|
|
|
|
|
|
|